---
title: "Resverlogix Faces Filing Delay as Alberta Regulator Reviews Cease Trade Request"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/281302637.md"
description: "Resverlogix Faces Filing Delay as Alberta Regulator Reviews Cease Trade Request"
datetime: "2026-04-01T04:43:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281302637.md)
  - [en](https://longbridge.com/en/news/281302637.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281302637.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/281302637.md) | [English](https://longbridge.com/en/news/281302637.md)


# Resverlogix Faces Filing Delay as Alberta Regulator Reviews Cease Trade Request

Resverlogix Faces Filing Delay as Alberta Regulator Reviews Cease Trade Request

### 相關股票

- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [Lexicon Pharma (LXRX.US)](https://longbridge.com/zh-HK/quote/LXRX.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [Lexaria Bioscience (LEXX.US)](https://longbridge.com/zh-HK/quote/LEXX.US.md)
- [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-HK/quote/LABU.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)

## 相關資訊與研究

- [Iterum Therapeutics Announces Filing of Winding Up Petition | ITRM Stock News](https://longbridge.com/zh-HK/news/280800007.md)
- [Revolution Medicines' Readout of Trial for Pancreatic Cancer Drug Likely Positive, Oppenheimer Says](https://longbridge.com/zh-HK/news/281049250.md)
- [Palisade Bio Shares Phase 1b PALI-2108 Data Showing Safety, PK and Early Crohn’s Efficacy Signals](https://longbridge.com/zh-HK/news/281229588.md)
- [Senti Biosciences Non-GAAP EPS of -$0.53 misses by $0.06](https://longbridge.com/zh-HK/news/280788653.md)
- [MAIA's Phase 2 Trial Shows Eight Lung Cancer Patients Surpassing Two Years Of Survival](https://longbridge.com/zh-HK/news/281329946.md)